26 related articles for article (PubMed ID: 622061)
1. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
Waldorff S; Buch J
Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
[TBL] [Abstract][Full Text] [Related]
2. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
Vitolo E; Gambini E; Larovere MT; Rusconi F; Vitali GM
Boll Soc Ital Cardiol; 1979; 24(7):775-7. PubMed ID: 554665
[No Abstract] [Full Text] [Related]
3. [Indication and experience with an intravenously administered aldosterone-antagonist (soldactone) (author's transl)].
Kirsch R
Schweiz Rundsch Med Prax; 1975 Nov; 64(44):1414-7. PubMed ID: 1236699
[No Abstract] [Full Text] [Related]
4. The effect of intravenous potassium canrenoate in patients with severe heart failure and digitalis toxicity.
Cristodorescu R; Puschita M; Deutsch G; Berger E; Luca C
Med Interne; 1977; 15(1):27-34. PubMed ID: 841250
[TBL] [Abstract][Full Text] [Related]
5. The role of potassium-canrenoate on 3H-noradrenaline uptake and metabolism of the rat heart.
Préda I; Sebeszta M; Harsányi A; Szabó G; Antalóczy Z
Acta Physiol Acad Sci Hung; 1978; 51(4):393-9. PubMed ID: 754480
[TBL] [Abstract][Full Text] [Related]
6. [Aldosterone antagonists in coronary insufficiency].
Osswald H
Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
[No Abstract] [Full Text] [Related]
7. Spirolactones: clinical and pharmacologic studies.
Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
[No Abstract] [Full Text] [Related]
8. A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Ostrenga A; Pitcock J; Pitcock M
Adv Nurse Pract; 2005 Jan; 13(1):34-7. PubMed ID: 15679290
[No Abstract] [Full Text] [Related]
9. [New aspects of digitalis therapy].
Erdmann E
Internist (Berl); 1983 Jul; 24(7):422-8. PubMed ID: 6350212
[No Abstract] [Full Text] [Related]
10. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
11. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.
Karim A
Drug Metab Rev; 1978; 8(1):151-88. PubMed ID: 363379
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
